Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648024 | 0.78 | ALDH1A1 (0.46) | LMNAMAPK1AOC3TSHRKDM4E | |
| SCHEMBL8984994 | 0.77 | ESR1 (0.44) | LMNATSHRKDM4EHIF1ACYP2D6 | |
| SCHEMBL9633963 | 0.76 | TSHR (0.46) | LMNAMAPK1AOC3TSHRKDM4E | |
| SCHEMBL22519675 | 0.74 | LMNA (0.46) | LMNAMAPK1AOC3TSHRKDM4E | |
| SCHEMBL1268813 | 0.74 | LMNA (0.46) | LMNAMAPK1AOC3TSHRKDM4E | |
| SCHEMBL775059 | 0.72 | TSHR (0.44) | TSHRCYP2D6SRC | |
| SCHEMBL3718532 | 0.72 | LMNA (0.41) | LMNAMAPK1AOC3TSHRKDM4E | |
| SCHEMBL6076547 | 0.70 | LMNA (0.43) | LMNAMAPK1AOC3TSHRKDM4E | |
| SCHEMBL1720646 | 0.69 | — | — | |
| SCHEMBL8067280 | 0.69 | TSHR (0.39) | LMNAMAPK1AOC3TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3996749-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | Cybrexa 3, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-1617873-B1 | Treatment of multi-drug resistant tumours by a conjugate of mitomycin C | ALZA CORP (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7303760-B2 | Method for treating multi-drug resistant tumors | ALZA CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7276248-B2 | Conjugate having a cleavable linkage for use in a liposome | ALZA CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1173222-B1 | CONJUGATE HAVING A CLEAVABLE LINKAGE FOR USE IN A LIPOSOME | ALZA CORP (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1617873-A2 | MITOMYCIN CONJUGATES CLEAVABLE BY THIOLS | Alza Corporation (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6984396-B2 | Conjugate having a cleavable linkage for use in a liposome | ALZA CORPORATION (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050271715-A1 | Conjugate having a cleavable linkage for use in a liposome | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2005-12-08 | — | — | US | disclosed |
| EP-1579874-A2 | Conjugate having a cleavable linkage for use in a liposome | ALZA Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004110497-A2 | MITOMYCIN CONJUGATES CLEAVABLE BY THIOLS | ALZA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040161455-A1 | Method for treating multi-drug resistant tumors | ALZA CORPORATION | 2004-08-19 | — | — | US | disclosed |
| US-20030054028-A1 | Conjugate having a cleavable linkage for use in a liposome | ALZA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-6365179-B1 | CONJUGATE FOR USE IN LIPOSOMAL DRUG-DELIVERY VEHICLE INCLUDING HYDROPHOBIC MOIETY SUITABLE FOR INCORPORATION INTO LIPOSOMAL LIPID BILAYER AND THERAPEUTIC DRUG COVALENTLY ATTACHED TO DITHIOBENZYL MOIETY IN ORTHO OR PARA POSITION | ALZA CORPORATION | 2002-04-02 | — | — | US | disclosed |
| EP-1173222-A2 | CONJUGATE HAVING A CLEAVABLE LINKAGE FOR USE IN A LIPOSOME | ALZA CORPORATION (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064484-A2 | CONJUGATE HAVING A CLEAVABLE LINKAGE FOR USE IN A LIPOSOME | ALZA CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050271715-A1 | Conjugate having a cleavable linkage for use in a liposome | LANCL1, LIPA, LYPLA2 | LMNA 2100/4885MAPK1 4668/4885AOC3 2238/4885 |
| US-20040161455-A1 | Method for treating multi-drug resistant tumors | CYP11A1, MGST3, ME3 | LMNA 670/4885MAPK1 4738/4885AOC3 963/4885 |
| US-20030054028-A1 | Conjugate having a cleavable linkage for use in a liposome | LANCL1, LIPA, LYPLA2 | LMNA 2100/4885MAPK1 4668/4885AOC3 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.